On the other hand, the report of an anti-AchR seropositive patient who had favourable cancer outcome without developing MG after anti-PD1 therapy, suggest that ICI could be safely administered in asymptomatic anti-AchR seropositive cancer patients [25]. The gene discussed is PDCD1; the disease is myasthenia gravis.